ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Jefferies Financial Group

Equities researchers at Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report issued on Friday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $80.00 price target on the specialty pharmaceutical company’s stock. Jefferies Financial Group’s target price points to a potential upside of 30.17% from the stock’s current price.

A number of other analysts have also issued reports on the company. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $85.00 target price on the stock. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Finally, Guggenheim raised their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $79.78.

ANI Pharmaceuticals Stock Down 2.8 %

ANIP opened at $61.46 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market capitalization of $1.34 billion, a PE ratio of -111.75 and a beta of 0.62. The business has a 50-day moving average of $58.14 and a 200-day moving average of $58.11. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,300 shares of company stock valued at $584,869. Company insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. Principal Financial Group Inc. grew its stake in shares of ANI Pharmaceuticals by 6.9% during the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after purchasing an additional 5,829 shares during the period. Victory Capital Management Inc. grew its holdings in shares of ANI Pharmaceuticals by 153.6% during the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after buying an additional 7,825 shares in the last quarter. Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals during the third quarter worth about $11,670,000. Natixis Advisors LLC grew its holdings in shares of ANI Pharmaceuticals by 56.2% during the third quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after buying an additional 6,545 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.